l-leucovorin

l-leucovorin 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Gastric Cancer、Gastroesophageal Junction Cancer、Biliary Tract Cancer、Pancreatic Ductal Adenocarcinoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 l-leucovorin 研究

• Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer

  III 期招募中意大利NCT06509126

• Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  III 期招募中美国澳大利亚加拿大新西兰NCT03959085

• A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC

  III 期招募中中国NCT03303495

• Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism

  II 期招募中美国NCT04060030

• Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer

  III 期招募中日本NCT04288999

• TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)

  I 期 / II 期招募中西班牙NCT07284277

• Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme

  II 期招募中法国NCT06475352

• A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  II 期招募中美国澳大利亚加拿大Puerto RicoNCT06124157

• Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL

  II 期 / III 期招募中中国NCT07059156

• AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

  II 期招募中美国澳大利亚加拿大中国NCT06219941

• Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma

  II 期招募中法国NCT06846346

• FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.

  III 期招募中意大利NCT06733038

• Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

  III 期招募中意大利NCT06897644

• Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery

  III 期招募中奥地利NCT06391892

• Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

  I 期招募中美国NCT04847063

• Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

  I 期 / II 期招募中美国比利时中国法国NCT06324357

• Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer

  III 期招募中意大利西班牙NCT07389265

• Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  II 期招募中美国Puerto RicoNCT06317662

• Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature

  III 期招募中德国瑞典NCT05314998

• mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients

  II 期招募中中国NCT04084496

• Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer

  III 期招募中西班牙NCT06783491

• A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC

  II 期招募中日本NCT07733180

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。